FDA OKs new use for J&J's Xarelto

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 14, 2019 at 10:12 AM.

  1. #1 cafead, Oct 14, 2019 at 10:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via The FDA approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical's blood thinner XARELTO (rivaroxaban) for the prevention of venous thromboembolism (blood clots) in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

    article source
     
    Quote

Reply to Thread